Plain-English translation of NCT06508307 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing GC001, a new type of cancer treatment that uses a modified vaccinia virus (a harmless relative of the smallpox virus) injected directly into your tumor. Researchers want to find the safest and most effective dose of this treatment and see if it can help shrink tumors while triggering your immune system to fight cancer.
Many advanced cancers stop responding to standard treatments. This medication is designed to work in a new way—by infecting cancer cells directly and causing them to die while also activating your body's own immune system to attack the tumor.
You likely qualify if…
You likely don't qualify if…
You will receive a single injection of the treatment directly into your tumor—the injection volume depends on the size of your tumor. After receiving the injection, you will be closely monitored for 28 days to watch for any side effects. During this time, the researchers will take blood samples and do scans to see if the tumor is responding and to understand how the treatment is working in your body.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
China